BioSpace News Archive

Vyant Bio, Inc. is an innovative biotechnology company reinventing drug discovery for complex neurodevelopmental and neurodegenerative disorders.

BD (Becton, Dickinson and Company) today announced a new instrument for single-cell multiomics analysis that will enable scientists to run high-throughput studies without sacrificing sample integrity – potentially accelerating time to discovery across a wide range of disciplines including immunology, genetic disease research, and cancer and chronic disease research.

Ambrx Biopharma, Inc. has appointed Sandra Aung, Ph.D., as Executive Vice President, Head of Clinical Development.

Ensysce Biosciences, Inc. today announced that it has entered into a definitive agreement for the purchase and sale of 3,571,431 shares of the Company’s common stock at a purchase price of $0.84 per share of common stock.

Personalis, Inc. and Moderna, Inc. today announced the companies have signed a new agreement to continue using the Personalis NeXT Platform® as part of upcoming clinical studies evaluating mRNA-4157/V940.

Tenax Therapeutics, Inc. announced today the pricing of a public offering of (i) 8,666,666 shares of its common stock (or pre-funded warrants in lieu thereof) and (ii) warrants to purchase up to 17,333,332 shares of its common stock.

Terran Biosciences (“Terran”), a biotech platform company dedicated to the development of transformational therapeutics for neurological and psychiatric diseases, has announced the publication of PCT patent applications covering novel prodrugs of DMT, 5-MeO-DMT, and MDMA.

SpyGlass Pharma, a privately held ophthalmic therapeutics company, released 6-month data from a First-in-Human glaucoma treatment trial showing that its breakthrough drug delivery platform continues to demonstrate significant intraocular pressure (IOP) lowering in patients with glaucoma or ocular hypertension.

Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) (“Kiora” or the “Company”) today announced that it has entered into a common stock purchase agreement for a committed equity financing (the “Purchase Agreement”) with Lincoln Park Capital Fund, LLC (“LPC”), a long-standing investor in the Company.

February 3, 2023, Austin, Texas. TRYAL, an eClinical software platform company officially announced their launch today with $6 million in funding and technology designed to revolutionize the clinical trials technology landscape.